<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33284114</PMID><DateCompleted><Year>2021</Year><Month>04</Month><Day>14</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>31</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1474-4457</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>4</Issue><PubDate><Year>2021</Year><Month>Apr</Month></PubDate></JournalIssue><Title>The Lancet. Infectious diseases</Title><ISOAbbreviation>Lancet Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Safety and immunogenicity of inactivated poliovirus vaccine schedules for the post-eradication era: a randomised open-label, multicentre, phase 3, non-inferiority trial.</ArticleTitle><Pagination><StartPage>559</StartPage><EndPage>568</EndPage><MedlinePgn>559-568</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S1473-3099(20)30555-7</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1473-3099(20)30555-7</ELocationID><Abstract><AbstractText Label="BACKGROUND">Following the global eradication of wild poliovirus, countries using live attenuated oral poliovirus vaccines will transition to exclusive use of inactivated poliovirus vaccine (IPV) or fractional doses of IPV (f-IPV; a f-IPV dose is one-fifth of a normal IPV dose), but IPV supply and cost constraints will necessitate dose-sparing strategies. We compared immunisation schedules of f-IPV and IPV to inform the choice of optimal post-eradication schedule.</AbstractText><AbstractText Label="METHODS">This randomised open-label, multicentre, phase 3, non-inferiority trial was done at two centres in Panama and one in the Dominican Republic. Eligible participants were healthy 6-week-old infants with no signs of febrile illness or known allergy to vaccine components. Infants were randomly assigned (1:1:1:1, 1:1:1:2, 2:1:1:1), using computer-generated blocks of four or five until the groups were full, to one of four groups and received: two doses of intradermal f-IPV (administered at 14 and 36 weeks; two f-IPV group); or three doses of intradermal f-IPV (administered at 10, 14, and 36 weeks; three f-IPV group); or two doses of intramuscular IPV (administered at 14 and 36 weeks; two IPV group); or three doses of intramuscular IPV (administered at 10, 14, and 36 weeks; three IPV group). The primary outcome was seroconversion rates based on neutralising antibodies for poliovirus type 1 and type 2 at baseline and at 40 weeks (4 weeks after the second or third vaccinations) in the per-protocol population to allow non-inferiority and eventually superiority comparisons between vaccines and regimens. Three co-primary outcomes concerning poliovirus types 1 and 2 were to determine if seroconversion rates at 40 weeks of age after a two-dose regimen (administered at weeks 14 and 36) of intradermally administered f-IPV were non-inferior to a corresponding two-dose regimen of intramuscular IPV; if seroconversion rates at 40 weeks of age after a two-dose IPV regimen (weeks 14 and 36) were non-inferior to those after a three-dose IPV regimen (weeks 10, 14, and 36); and if seroconversion rates after a two-dose f-IPV regimen (weeks 14 and 36) were non-inferior to those after a three-dose f-IPV regimen (weeks 10, 14, and 36). The non-inferiority boundary was set at -10% for the lower bound of the two-sided 95% CI for the seroconversion rate difference.. Safety was assessed as serious adverse events and important medical events. This study is registered on ClinicalTrials.gov, NCT03239496.</AbstractText><AbstractText Label="FINDINGS">From Oct 23, 2017, to Nov 13, 2018, we enrolled 773 infants (372 [48%] girls) in Panama and the Dominican Republic (two f-IPV group n=217, three f-IPV group n=178, two IPV group n=178, and three IPV group n=200). 686 infants received all scheduled vaccine doses and were included in the per-protocol analysis. We observed non-inferiority for poliovirus type 1 seroconversion rate at 40 weeks for the two f-IPV dose schedule (95&#xb7;9% [95% CI 92&#xb7;0-98&#xb7;2]) versus the two IPV dose schedule (98&#xb7;7% [95&#xb7;4-99&#xb7;8]), and for the three f-IPV dose schedule (98&#xb7;8% [95&#xb7;6-99&#xb7;8]) versus the three IPV dose schedule (100% [97&#xb7;9-100]). Similarly, poliovirus type 2 seroconversion rate at 40 weeks for the two f-IPV dose schedule (97&#xb7;9% [94&#xb7;8-99&#xb7;4]) versus the two IPV dose schedule (99&#xb7;4% [96&#xb7;4-100]), and for the three f-IPV dose schedule (100% [97&#xb7;7-100]) versus the three IPV dose schedule (100% [97&#xb7;9-100]) were non-inferior. Seroconversion rate for the two f-IPV regimen was statistically superior 4 weeks after the last vaccine dose in the 14 and 36 week schedule (95&#xb7;9% [92&#xb7;0-98&#xb7;2]) compared with the 10 and 14 week schedule (83&#xb7;2% [76&#xb7;5-88&#xb7;6]; p=0&#xb7;0062) for poliovirus type 1. Statistical superiority of the 14 and 36 week schedule was also found for poliovirus type 2 (14 and 36 week schedule 97&#xb7;9% [94&#xb7;8-99&#xb7;4] vs 10 and 14 week schedule 83&#xb7;9% [77&#xb7;2-89&#xb7;2]; p=0&#xb7;0062), and poliovirus type 3 (14 and 36 week schedule 84&#xb7;5% [78&#xb7;7-89&#xb7;3] vs 10 and 14 week schedule 73&#xb7;3% [65&#xb7;8-79&#xb7;9]; p=0&#xb7;0062). For IPV, a two dose regimen administered at 14 and 36 weeks (99&#xb7;4% [96&#xb7;4-100]) was superior a 10 and 14 week schedule (88&#xb7;9% [83&#xb7;4-93&#xb7;1]; p&lt;0&#xb7;0001) for poliovirus type 2, but not for type 1 (14 and 36 week schedule 98&#xb7;7% [95&#xb7;4-99&#xb7;8] vs 10 and 14 week schedule 95&#xb7;6% [91&#xb7;4-98&#xb7;1]), or type 3 (14 and 36 week schedule 97&#xb7;4% [93&#xb7;5-99&#xb7;3] vs 10 and 14 week schedule 93&#xb7;9% [89&#xb7;3-96&#xb7;9]). There were no related serious adverse events or important medical events reported in any group showing safety was unaffected by administration route or schedule.</AbstractText><AbstractText Label="INTERPRETATION">Our observations suggest that adequate immunity against poliovirus type 1 and type 2 is provided by two doses of either IPV or f-IPV at 14 and 36 weeks of age, and broad immunity is provided with three doses of f-IPV, enabling substantial savings in cost and supply. These novel clinical data will inform global polio immunisation policy for the post-eradication era.</AbstractText><AbstractText Label="FUNDING">Bill &amp; Melinda Gates Foundation.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bandyopadhyay</LastName><ForeName>Ananda S</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Polio, Global Development, Bill &amp; Melinda Gates Foundation, Seattle, USA. Electronic address: ananda.bandyopadhyay@gatesfoundation.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gast</LastName><ForeName>Chris</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Biostatistics Consultant, Seattle, Washington, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rivera</LastName><ForeName>Luis</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Hospital Maternidad Nuestra Se&#xf1;ora de la Altagracia, Santo Domingo, Dominican Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>S&#xe1;ez-Llorens</LastName><ForeName>Xavier</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Infectious Disease, Hospital del Ni&#xf1;o Dr Jos&#xe9; Ren&#xe1;n Esquivel, Panama City, Panama.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oberste</LastName><ForeName>M Steven</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, CDC, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weldon</LastName><ForeName>William C</ForeName><Initials>WC</Initials><AffiliationInfo><Affiliation>Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, CDC, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Modlin</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Polio, Global Development, Bill &amp; Melinda Gates Foundation, Seattle, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Clemens</LastName><ForeName>Ralf</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Global Research in Infectious Diseases, Rio de Janeiro, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Costa Clemens</LastName><ForeName>Sue Ann</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Global Research in Infectious Diseases, Rio de Janeiro, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jimeno</LastName><ForeName>Jose</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Infectious Disease, Hospital del Ni&#xf1;o Dr Jos&#xe9; Ren&#xe1;n Esquivel, Panama City, Panama.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>R&#xfc;ttimann</LastName><ForeName>Ricardo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Fighting Infectious Diseases in Emerging Countries, Miami, FL, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT03239496</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType><PublicationType UI="D000073843">Equivalence Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>10</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Lancet Infect Dis</MedlineTA><NlmUniqueID>101130150</NlmUniqueID><ISSNLinking>1473-3099</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011054">Poliovirus Vaccine, Inactivated</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011055">Poliovirus Vaccine, Oral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004293" MajorTopicYN="N" Type="Geographic">Dominican Republic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007115" MajorTopicYN="Y">Immunization Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071497" MajorTopicYN="Y">Immunogenicity, Vaccine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007231" MajorTopicYN="N">Infant, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010176" MajorTopicYN="N" Type="Geographic">Panama</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011051" MajorTopicYN="N">Poliomyelitis</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="N">Poliovirus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011054" MajorTopicYN="N">Poliovirus Vaccine, Inactivated</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011055" MajorTopicYN="N">Poliovirus Vaccine, Oral</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069078" MajorTopicYN="N">Seroconversion</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>4</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>5</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>6</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>12</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>4</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>12</Month><Day>7</Day><Hour>12</Hour><Minute>9</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>4</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33284114</ArticleId><ArticleId IdType="pmc">PMC7992032</ArticleId><ArticleId IdType="doi">10.1016/S1473-3099(20)30555-7</ArticleId><ArticleId IdType="pii">S1473-3099(20)30555-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Global Polio Eradication Initiative  Polio endgame strategy 2019-2023: eradication, integration, certification and containment. 2019. http://polioeradication.org/wp-content/uploads/2019/06/english-polio-endgame-strategy.pdf</Citation></Reference><Reference><Citation>Sabin AB. Oral poliovirus vaccine: history of its development and use and current challenge to eliminate poliomyelitis from the world. J Infect Dis. 1985;151:420&#x2013;423.</Citation><ArticleIdList><ArticleId IdType="pubmed">2982959</ArticleId></ArticleIdList></Reference><Reference><Citation>Global Polio Eradication Initiative  Wild poliovirus list: List of wild poliovirus by country and year. 2010. http://polioeradication.org/polio-today/polio-now/wild-poliovirus-list/</Citation></Reference><Reference><Citation>WHO Meeting of the Strategic Advisory Group of Experts on immunization, October 2015&#x2014;conclusions and recommendations. Wkly Epidemiol Rec. 2015;50:681&#x2013;700.</Citation><ArticleIdList><ArticleId IdType="pubmed">26685390</ArticleId></ArticleIdList></Reference><Reference><Citation>Bandyopadhyay AS, Garon J, Seib K, Orenstein WA. Polio vaccination: past, present and future. Future Microbiol. 2015;10:791&#x2013;808.</Citation><ArticleIdList><ArticleId IdType="pubmed">25824845</ArticleId></ArticleIdList></Reference><Reference><Citation>Jorba J, Diop OM, Iber J. Update on vaccine-derived poliovirus outbreaks - worldwide, January 2018&#x2013;June 2019. MMWR Morb Mortal Wkly Rep. 2019;68:1024&#x2013;1028.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6855511</ArticleId><ArticleId IdType="pubmed">31725706</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Ryan M, Bandyopadhyay AS, Villena R. Inactivated poliovirus vaccine given alone or in a sequential schedule with bivalent oral poliovirus vaccine in Chilean infants: a randomised, controlled, open-label, phase 4, non-inferiority study. Lancet Infect Dis. 2015;15:1273&#x2013;1282.</Citation><ArticleIdList><ArticleId IdType="pubmed">26318714</ArticleId></ArticleIdList></Reference><Reference><Citation>S&#xe1;ez-Llorens X, Clemens R, Leroux-Roels G. Immunogenicity and safety of a novel monovalent high-dose inactivated poliovirus type 2 vaccine in infants: a comparative, observer-blind, randomised, controlled trial. Lancet Infect Dis. 2016;16:321&#x2013;330.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9108810</ArticleId><ArticleId IdType="pubmed">26719058</ArticleId></ArticleIdList></Reference><Reference><Citation>Asturias EJ, Bandyopadhyay AS, Self S. Humoral and intestinal immunity induced by new schedules of bivalent oral poliovirus vaccine and one or two doses of inactivated poliovirus vaccine in Latin American infants: an open-label randomised controlled trial. Lancet. 2016;388:158&#x2013;169.</Citation><ArticleIdList><ArticleId IdType="pubmed">27212429</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu R, Altamirano J, Sarnquist CC, Maldonado YA, Andrews JR. Assessing the risk of vaccine-derived outbreaks after reintroduction of oral poliovirus vaccine in postcessation settings. Clin Infect Dis. 2018;67(suppl 1):S26&#x2013;S34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6206116</ArticleId><ArticleId IdType="pubmed">30376087</ArticleId></ArticleIdList></Reference><Reference><Citation>Bandyopadhyay AS, Modlin JF, Wenger J, Gast C. Immunogenicity of new primary immunization schedules with inactivated poliovirus vaccine and bivalent oral polio vaccine for the polio endgame: a review. Clin Infect Dis. 2018;67(suppl 1):S35&#x2013;S41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6206125</ArticleId><ArticleId IdType="pubmed">30376081</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis I, Ottosen A, Rubin J, Blanc DC, Zipursky S, Wootton E. A supply and demand management perspective on the accelerated global introductions of inactivated poliovirus vaccine in a constrained supply market. J Infect Dis. 2017;216(suppl 1):S33&#x2013;S39.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5853471</ArticleId><ArticleId IdType="pubmed">28838159</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan American Health Organization  TAG recommendations about the use of IPV. 2016. https://www.paho.org/hq/index.php?option=com_content&amp;view=article&amp;id=12134:tag-recommendations-ipv&amp;Itemid=0&amp;lang=en</Citation></Reference><Reference><Citation>UNICEF  Inactivated polio vaccine: supply update, August 2019. 2019. https://www.unicef.org/supply/files/ipv-inactivated-polio-vaccine-supply-update.pdf</Citation></Reference><Reference><Citation>Alfaro-Murillo JA, &#xc1;vila-Ag&#xfc;ero ML, Fitzpatrick MC, Crystal CJ, Falleiros-Arlant L-H, Galvani AP. The case for replacing live oral polio vaccine with inactivated vaccine in the Americas. Lancet. 2020;395:1163&#x2013;1166.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8572547</ArticleId><ArticleId IdType="pubmed">32247397</ArticleId></ArticleIdList></Reference><Reference><Citation>Kinder M. Eliminating Polio in Latin America and the Caribbean: a case study. 2007. https://www.cgdev.org/sites/default/files/archive/doc/millions/MS_case_5.pdf</Citation></Reference><Reference><Citation>Weldon WC, Oberste MS, Pallansch MA. Standardized methods for detection of poliovirus antibodies. In: Mart&#xed;n J, editor. Poliovirus: Methods in Molecular Biology. Humana Press; New York: 2016. pp. 145&#x2013;176.</Citation><ArticleIdList><ArticleId IdType="pubmed">26983734</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohammed AJ, Al Awaidy S, Bawikar S. Fractional doses of inactivated poliovirus vaccine in Oman. N Engl J Med. 2010;362:2351&#x2013;2359.</Citation><ArticleIdList><ArticleId IdType="pubmed">20573923</ArticleId></ArticleIdList></Reference><Reference><Citation>Resik S, Tejeda A, Sutter RW. Priming after a fractional dose of inactivated poliovirus vaccine. N Engl J Med. 2013;368:416&#x2013;424.</Citation><ArticleIdList><ArticleId IdType="pubmed">23363495</ArticleId></ArticleIdList></Reference><Reference><Citation>Sutter RW, Pallansch MA, Sawyer LA, Cochi SL, Hadler SC. Defining surrogate serologic tests with respect to predicting protective vaccine efficacy: poliovirus vaccination. Ann NY Acad Sci. 1995;754:289&#x2013;299.</Citation><ArticleIdList><ArticleId IdType="pubmed">7625665</ArticleId></ArticleIdList></Reference><Reference><Citation>Plotkin SA. Correlates of protection induced by vaccination. Clin Vaccine Immunol. 2010;17:1055&#x2013;1065.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2897268</ArticleId><ArticleId IdType="pubmed">20463105</ArticleId></ArticleIdList></Reference><Reference><Citation>Vidor E. Poliovirus vaccine inactivated. In: Plotkin SA, Orenstein WA, Offit PA, Edwards KM, editors. Vaccines. 7th edn. Elsevier-Saunders; Philadelphia, PA: 2018. pp. 841&#x2013;865.</Citation></Reference><Reference><Citation>Iqbal S, Shi J, Seib K. Preparation for global introduction of inactivated poliovirus vaccine: safety evidence from the US Vaccine Adverse Event Reporting System, 2000&#x2013;12. Lancet Infect Dis. 2015;15:1175&#x2013;1182.</Citation><ArticleIdList><ArticleId IdType="pubmed">26289956</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO  Polio vaccines: WHO position paper &#x2013; March, 2016. 2016. https://www.who.int/wer/2016/wer9112.pdf?ua=1</Citation><ArticleIdList><ArticleId IdType="pubmed">27894720</ArticleId></ArticleIdList></Reference><Reference><Citation>Grassly N. Immunogenicity and effectiveness of routine immunization with 1 or 2 doses of inactivated poliovirus vaccine: systematic review and meta-analysis. J Infect Dis. 2014;210(suppl 1):S439&#x2013;S446.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4197908</ArticleId><ArticleId IdType="pubmed">24634499</ArticleId></ArticleIdList></Reference><Reference><Citation>Anand A, Molodecky NA, Pallansch MA, Sutter RW. Immunogenicity to poliovirus type 2 following two doses of fractional intradermal inactivated poliovirus vaccine: a novel dose sparing immunization schedule. Vaccine. 2017;35:2993&#x2013;2998.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10423713</ArticleId><ArticleId IdType="pubmed">28434691</ArticleId></ArticleIdList></Reference><Reference><Citation>Resik S, Tejeda A, Lago PM. Randomized controlled clinical trial of fractional doses of inactivated poliovirus vaccine administered intradermally by needle-free device in Cuba. J Infect Dis. 2010;201:1344&#x2013;1352.</Citation><ArticleIdList><ArticleId IdType="pubmed">20350164</ArticleId></ArticleIdList></Reference><Reference><Citation>Anand A, Zaman K, Est&#xed;variz CF. Early priming with inactivated poliovirus vaccine (IPV) and intradermal fractional dose IPV administered by a microneedle device: a randomized controlled trial. Vaccine. 2015;33:6816&#x2013;6822.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10423714</ArticleId><ArticleId IdType="pubmed">26476367</ArticleId></ArticleIdList></Reference><Reference><Citation>Resik S, Mach O, Tejeda A. Immunogenicity of intramuscular fractional dose of inactivated poliovirus vaccine. J Infect Dis. 2020;221:895&#x2013;901.</Citation><ArticleIdList><ArticleId IdType="pubmed">31242300</ArticleId></ArticleIdList></Reference><Reference><Citation>Gamage D, Ginige S, Palihawadana P. National introduction of fractional-dose inactivated polio vaccine in Sri Lanka following the global &#x201c;switch&#x201d;. WHO South East Asia J Public Health. 2018;7:79&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">30136665</ArticleId></ArticleIdList></Reference><Reference><Citation>Bandyopadhyay AS, Orenstein WA. Evolution of inactivated poliovirus vaccine use for the endgame and beyond. J Infect Dis. 2020;221:861&#x2013;863.</Citation><ArticleIdList><ArticleId IdType="pubmed">31242297</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>